{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Andersen J"],"funding":["National Health Medical Research Council (Australia","MS Australia","Sydney Research Excellence Initiative 2020"],"pagination":["109-119"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC12911599"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["97(2)"],"pubmed_abstract":["<h4>Background</h4>Detection of immunoglobulin G targeting myelin oligodendrocyte glycoprotein (MOG-IgG) is the mainstay of laboratory diagnosis of MOG antibody-associated disease. Laboratory biomarkers have the potential to predict disease course and activity, thus informing prompt therapeutic decisions to minimise relapse-associated disability accrual.<h4>Methods</h4>This systematic review with meta-analysis was registered in PROSPERO (CRD42024554429). MEDLINE, Embase and Scopus databases were searched. Random-effects or mixed-effects modelling was performed and OR or HR with 95% CIs reported.<h4>Results</h4>106 studies with ≥1710 individuals were included. A relapsing course was associated with persistent seropositivity on serial samples collected ≥3 months apart (OR 2.7 (95% CI 1.8 to "],"journal":["Journal of neurology, neurosurgery, and psychiatry"],"pubmed_title":["Biomarkers to predict relapse in myelin oligodendrocyte glycoprotein antibody-associated disease: a systematic review and meta-analysis."],"pmcid":["PMC12911599"],"funding_grant_id":["RCD GNT1193648","N/A","FB GNT2016841","SR GNT2008339"],"pubmed_authors":["Trewin BP","Ramanathan S","Dale RC","Andersen J","Brilot F"],"additional_accession":[]},"is_claimable":false,"name":"Biomarkers to predict relapse in myelin oligodendrocyte glycoprotein antibody-associated disease: a systematic review and meta-analysis.","description":"<h4>Background</h4>Detection of immunoglobulin G targeting myelin oligodendrocyte glycoprotein (MOG-IgG) is the mainstay of laboratory diagnosis of MOG antibody-associated disease. Laboratory biomarkers have the potential to predict disease course and activity, thus informing prompt therapeutic decisions to minimise relapse-associated disability accrual.<h4>Methods</h4>This systematic review with meta-analysis was registered in PROSPERO (CRD42024554429). MEDLINE, Embase and Scopus databases were searched. Random-effects or mixed-effects modelling was performed and OR or HR with 95% CIs reported.<h4>Results</h4>106 studies with ≥1710 individuals were included. A relapsing course was associated with persistent seropositivity on serial samples collected ≥3 months apart (OR 2.7 (95% CI 1.8 to ","dates":{"release":"2026-01-01T00:00:00Z","publication":"2026 Jan","modification":"2026-07-16T00:42:03.271Z","creation":"2026-07-09T10:26:11.047Z"},"accession":"S-EPMC12911599","cross_references":{"pubmed":["41033784"],"doi":["10.1136/jnnp-2025-337039"]}}